EA
VYGR icon

Emerald Acquisition’s Voyager Therapeutics VYGR Stock Holding History

Emerald Acquisition’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$179K Sell
14,909
-28,277
-65% -$383K ﹤0.01% 2717
2016
Q2 		$475K Buy
+43,186
New +$528K ﹤0.01% 2486

Other funds holding VYGR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Emerald Acquisition's VYGR Position: Q3 2016 in Review

Emerald Acquisition reduced its Voyager Therapeutics (VYGR) stake by 65% in Q3 2016, selling an estimated $383K and leaving 14,909 shares worth $179K. The position accounts for ﹤0.01% of the portfolio, ranked #2717.

Emerald Acquisition first reported a position in VYGR in Q2 2016 and has held it in 2 quarters since. The position peaked at $475K in Q2 2016. 52 funds tracked by Wall St. Rank hold VYGR as of Q3 2016.

  • Emerald Acquisition held 14,909 shares of Voyager Therapeutics worth $179K as of Q3 2016.
  • Emerald Acquisition sold 28,277 Voyager Therapeutics shares in Q3 2016, an estimated $383K.
  • Voyager Therapeutics made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2717 holding.
  • Emerald Acquisition first reported a position in Voyager Therapeutics in Q2 2016 and has held it in 2 quarters since.
  • Emerald Acquisition's Voyager Therapeutics position peaked at $475K in Q2 2016.
  • 52 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.